Omalizumab

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search

Omalizumab (Xolair) is a medication originally designed to reduce sensitivity to allergens and is used for treating chronic idiopathic urticaria and allergic asthma.

It is a monoclonal antibody that binds to free immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B cells. It inhibits the binding of IgE to FcεRI on mast cells and basophils by binding to an antigenic epitope on IgE that overlaps with the site to which FcεRI binds. In this sense, it is a potent mast cell stabilizer.

References[edit | edit source]


The information provided at this site is not intended to diagnose or treat any illness.

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history